Search Results - "Leonardi, G.C."

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma by Skoulidis, F., Hellman, M.D., Awad, M., Gainor, J.F., Rizvi, H., Carter, B., Denning, W.L., Villalobos, P., Parra, E.R., Elamin, Y.Y., Zhang, J., Leonardi, G.C., Halpenny, D.F., Papadimitrakopoulou, V., Wistuba, I.I., Wolchok, J.D., Shaw, A.T., Jänne, P.A., Rudin, C.M., Heymach, J.V.

Get full text